Oral hyaluronic acid works only if the molecular weight fraction is small enough to cross the intestinal epithelium. High-molecular-weight HA (over 1 MDa, typical of injectable-grade material) does not absorb intact via oral route. Low-molecular-weight fractions (under ~500 kDa) are absorbed in humans and reach systemic circulation. 120 kDa sits within that absorbable range and is the fraction most consistently referenced in human oral HA joint studies. Labels that do not disclose the kDa are failing a basic bioavailability transparency standard.

Key takeaways

HA molecular weight ranges from ~10 kDa to several MDa. The same molecule, folded into different chain lengths, behaves very differently in the gut.
Only low-molecular-weight HA absorbs orally. Over ~500 kDa, the molecule is degraded or excreted without crossing the gut wall.
120 kDa is the clinically tested midpoint. It absorbs reliably and is the fraction most studies on oral HA joint support have used.
Oral HA is not injectable HA. Injectable-grade HA acts locally in the joint capsule. Oral HA acts systemically via gut absorption and lymphatic uptake.
No kDa on the label = no way to assess absorption. Transparency is the first filter before evaluating dose or evidence.

What HA does in the joint

Hyaluronic acid is a glycosaminoglycan found throughout the body, with the highest concentrations in synovial fluid, skin, and the vitreous humor of the eye. In the joint, HA is the molecule that gives synovial fluid its viscoelastic quality: thick and shock-absorbing under slow mechanical load, thinner and lubricating under rapid movement.

The body continuously synthesizes and degrades HA in the synovial compartment. Under chronic joint stress, inflammation, or aging, HA turnover can shift toward depletion. Supporting systemic HA pools through oral supplementation is one strategy to address that shift; injectable HA (placed directly into the joint capsule by a clinician) is a different strategy with a different time profile.

Molecular weight determines absorption

HA is a long polymer built from repeating disaccharide units. Commercial HA is available at molecular weights ranging from oligomeric forms (under 20 kDa) to several megadaltons (MDa). The molecular size directly affects whether the molecule can cross the intestinal epithelium intact.

Pharmacokinetic studies in rats, dogs, and humans (summarized in Balogh 2008, J Agric Food Chem, and in the Oe 2016 clinical review) converge on this pattern:

Very low MW (oligo HA, under 20 kDa): high absorption. However, short HA fragments can act as pro-inflammatory signaling molecules in some contexts, so lower is not automatically better.
Low MW (20-500 kDa): meaningful oral absorption. This range includes the 120 kDa fraction used in most oral HA joint research.
High MW (500 kDa to 1 MDa): partial absorption, primarily through the lymphatic system. Some bioavailability but inconsistent.
Very high MW (over 1 MDa, injectable grade): minimal oral absorption. Degraded or passed through the GI tract without reaching systemic circulation.

Oral HA products that do not disclose the molecular weight are selling a black box. The same milligram weight on the label can deliver meaningfully different systemic HA depending on which fraction is inside the capsule.

Why 120 kDa specifically

The 120 kDa fraction is the midpoint of the absorbable range. It is large enough to retain some of the signaling profile of native HA (which typically circulates at higher MW in healthy synovial fluid) and small enough to reliably cross the gut. It is also the fraction used in the majority of human oral HA studies that have shown joint-comfort improvement on validated scales (WOMAC, VAS).

The Kalman 2008 trial in Nutrition Journal tested a natural HA extract standardized in the low-MW range in women with symptomatic knee osteoarthritis. The oral HA arm showed measurable improvement in pain scores over 8 weeks compared to placebo. The Oe 2016 systematic review summarized multiple RCTs of oral HA at absorbable MW fractions, concluding that oral HA supplementation supports knee joint comfort in adults with mild-to-moderate joint symptoms.

Comparison: absorption by MW fraction

Fraction	Oral bioavailability	Typical use case
Oligo HA (<20 kDa)	High	Research, specific signaling studies
120 kDa (low MW)	Meaningfully absorbed	Oral joint support (clinically tested)
500-1000 kDa (medium MW)	Partial	Topical, cosmetic, some oral
>1 MDa (high MW, injectable grade)	Minimal oral	Intra-articular injection only

Oral HA vs injectable HA: different tools

Intra-articular HA injections (hyaluronate viscosupplementation, commercial brands like Synvisc, Euflexxa, Orthovisc) are placed directly into the joint capsule by a clinician. The HA used is high molecular weight (over 1 MDa) and acts locally on the synovial fluid viscoelasticity immediately. It does not circulate systemically in meaningful amounts.

Oral HA at low MW is absorbed through the gut, enters the lymphatic system and systemic circulation, and contributes to the body's ongoing HA turnover. It supports joint function over weeks of consistent daily use. It does not produce the immediate local effect of an injection.

The two approaches are complementary, not interchangeable. A patient receiving HA injections may also benefit from oral HA for baseline systemic turnover between injection cycles, but this is a clinical decision that depends on the specific situation.

What to look for on the label

Molecular weight disclosed in kDa or Da. If absent, treat as a red flag.
Specific fraction, not a range. "Low molecular weight" is marketing. "120 kDa" or "100-150 kDa" is documentation.
Source and manufacturing. Microbial fermentation produces pharma-grade HA without animal-origin concerns. Rooster comb extraction is older and has allergen considerations for some individuals.
Dose in mg. Clinical trials on oral HA for joint support cluster around 80-200 mg per day of low-MW HA.
Third-party testing. Purity of the HA fraction matters as much as the average MW.

Frequently asked

If oral HA is absorbed, why do doctors still give injections?

Because the two approaches solve different problems on different time horizons. Injections place high-MW HA directly into a specific joint for immediate local viscoelastic support. Oral HA contributes to systemic HA turnover over weeks. For acute viscoelastic support of a specific joint, injection is faster. For ongoing systemic support with no procedural overhead, oral is the tool.

Is more HA always better?

No. Clinical trials cluster around 80-200 mg per day of low-MW HA. Above that, the marginal benefit plateaus. Below about 40 mg, the plasma signal is inconsistent in pharmacokinetic studies.

Does HA interact with any medications?

Oral HA has no well-documented pharmacological interactions with common medications. Individuals on immunosuppressants or with active infections should discuss with their physician before starting any new supplement, including HA.

Can I take HA if I have had knee injections?

In principle yes, since the two routes do not interfere. Discuss with the prescriber of the injection protocol, especially regarding timing relative to injection cycles.

How does Vyos handle this?

OsteoGuard uses hyaluronic acid standardized at 120 kDa, within the absorbable range documented in human pharmacokinetic studies. Dose and formulation details on the hyaluronic acid ingredient page, or the OsteoGuard product page.

References

Oe M, Tashiro T, Yoshida H, et al. Oral hyaluronan relieves knee pain: a review. Nutrition Journal. 2016. PMID 26818459
Balogh L, Polyak A, Mathe D, et al. Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs. Journal of Agricultural and Food Chemistry. 2008. PMID 19053387
Kalman DS, Heimer M, Valdeon A, et al. Effect of a natural extract of chicken combs with a high content of hyaluronic acid in women with symptomatic knee osteoarthritis. Nutrition Journal. 2008. PMID 18416885

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. If you are pregnant, nursing, under 18, taking prescription medication, or receiving intra-articular injections, consult your physician before starting oral HA supplementation.